43.2 USD
+1 (+2.37%)
43.2 USD
0 (0%)
Taking everything into account, KNSA scores 6 out of 10 in our fundamental rating. KNSA was compared to 525 industry peers in the Biotechnology industry. While KNSA has a great health rating, its profitability is only average at the moment. KNSA has both an excellent growth and valuation score. This means it is growing and it is still cheap. This is a rare combination! This makes KNSA very considerable for value and growth investing!
1. Profitability
1.1 Basic Checks
- KNSA had positive earnings in the past year.
- In the past year KNSA had a positive cash flow from operations.
- In multiple years KNSA reported negative net income over the last 5 years.
- The reported operating cash flow has been mixed in the past 5 years: KNSA reported negative operating cash flow in multiple years.
1.2 Ratios
- KNSA has a better Return On Assets (5.04%) than 91.43% of its industry peers.
- KNSA has a Return On Equity of 6.71%. This is amongst the best in the industry. KNSA outperforms 91.05% of its industry peers.
- KNSA's Return On Invested Capital of 5.12% is amongst the best of the industry. KNSA outperforms 92.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.04% | ||
| ROE | 6.71% | ||
| ROIC | 5.12% |
ROA(3y)11.71%
ROA(5y)-15.78%
ROE(3y)13.22%
ROE(5y)-19.49%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- With an excellent Profit Margin value of 6.01%, KNSA belongs to the best of the industry, outperforming 89.90% of the companies in the same industry.
- KNSA has a better Operating Margin (6.38%) than 90.10% of its industry peers.
- The Gross Margin of KNSA (87.52%) is better than 89.90% of its industry peers.
- In the last couple of years the Gross Margin of KNSA has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 6.38% | ||
| PM (TTM) | 6.01% | ||
| GM | 87.52% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.87%
GM growth 5YN/A
2. Health
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), KNSA is destroying value.
- The number of shares outstanding for KNSA has been increased compared to 1 year ago.
- Compared to 5 years ago, KNSA has more shares outstanding
- KNSA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
- KNSA has an Altman-Z score of 11.78. This indicates that KNSA is financially healthy and has little risk of bankruptcy at the moment.
- KNSA's Altman-Z score of 11.78 is amongst the best of the industry. KNSA outperforms 83.81% of its industry peers.
- There is no outstanding debt for KNSA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 11.78 |
ROIC/WACC0.55
WACC9.33%
2.3 Liquidity
- A Current Ratio of 3.85 indicates that KNSA has no problem at all paying its short term obligations.
- With a Current ratio value of 3.85, KNSA perfoms like the industry average, outperforming 46.10% of the companies in the same industry.
- KNSA has a Quick Ratio of 3.51. This indicates that KNSA is financially healthy and has no problem in meeting its short term obligations.
- With a Quick ratio value of 3.51, KNSA perfoms like the industry average, outperforming 44.19% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.85 | ||
| Quick Ratio | 3.51 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 421.43% over the past year.
- Looking at the last year, KNSA shows a very strong growth in Revenue. The Revenue has grown by 55.68%.
- Measured over the past years, KNSA shows a very strong growth in Revenue. The Revenue has been growing by 122.27% on average per year.
EPS 1Y (TTM)421.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%227.78%
Revenue 1Y (TTM)55.68%
Revenue growth 3Y122.27%
Revenue growth 5YN/A
Sales Q2Q%61.17%
3.2 Future
- KNSA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 47.22% yearly.
- KNSA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 24.42% yearly.
EPS Next Y263.59%
EPS Next 2Y119.11%
EPS Next 3Y77.58%
EPS Next 5Y47.22%
Revenue Next Year59.15%
Revenue Next 2Y44.49%
Revenue Next 3Y33.95%
Revenue Next 5Y24.42%
3.3 Evolution
- The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
- A Price/Earnings ratio of 96.00 indicates a quite expensive valuation of KNSA.
- KNSA's Price/Earnings ratio is rather cheap when compared to the industry. KNSA is cheaper than 89.90% of the companies in the same industry.
- Compared to an average S&P500 Price/Earnings ratio of 27.25, KNSA is valued quite expensively.
- A Price/Forward Earnings ratio of 25.29 indicates a quite expensive valuation of KNSA.
- Based on the Price/Forward Earnings ratio, KNSA is valued cheaply inside the industry as 92.57% of the companies are valued more expensively.
- The average S&P500 Price/Forward Earnings ratio is at 25.98. KNSA is around the same levels.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 96 | ||
| Fwd PE | 25.29 |
4.2 Price Multiples
- 90.29% of the companies in the same industry are more expensive than KNSA, based on the Enterprise Value to EBITDA ratio.
- Based on the Price/Free Cash Flow ratio, KNSA is valued cheaply inside the industry as 93.90% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 32.19 | ||
| EV/EBITDA | 69.25 |
4.3 Compensation for Growth
- The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- KNSA has a very decent profitability rating, which may justify a higher PE ratio.
- KNSA's earnings are expected to grow with 77.58% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.36
PEG (5Y)N/A
EPS Next 2Y119.11%
EPS Next 3Y77.58%
5. Dividend
5.1 Amount
- No dividends for KNSA!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
KINIKSA PHARMACEUTICALS INTE / KNSA FAQ
Can you provide the ChartMill fundamental rating for KINIKSA PHARMACEUTICALS INTE?
ChartMill assigns a fundamental rating of 6 / 10 to KNSA.
Can you provide the valuation status for KINIKSA PHARMACEUTICALS INTE?
ChartMill assigns a valuation rating of 7 / 10 to KINIKSA PHARMACEUTICALS INTE (KNSA). This can be considered as Undervalued.
Can you provide the profitability details for KINIKSA PHARMACEUTICALS INTE?
KINIKSA PHARMACEUTICALS INTE (KNSA) has a profitability rating of 6 / 10.
Can you provide the PE and PB ratios for KNSA stock?
The Price/Earnings (PE) ratio for KINIKSA PHARMACEUTICALS INTE (KNSA) is 96 and the Price/Book (PB) ratio is 6.12.
How financially healthy is KINIKSA PHARMACEUTICALS INTE?
The financial health rating of KINIKSA PHARMACEUTICALS INTE (KNSA) is 7 / 10.